I've highlighted 3 important lines to follow on AVCO's chart above.
At close on Monday, AVCO was trading above its 50-Day Simple Moving Average (SMA) and its 13-Day Exponential Moving Average.
Now, if it is able to clear through resistance at its 200-Day SMA in the near term, it could provide a breakout spark towards a potential squeeze.
These 3 lines will be vital to watch closely this week.
No. 2 AVCO Potential Catalyst - Low Float Could Allow For Daily Volatility (+ Explosive Chart History)
According to the Yahoo Finance website, AVCO has a low float.
The website reports this profile to have approximately 37.78Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could more positive company news before the end of the year help provide a near term spark?
On top of that, take another look at AVCO's chart above and check out its explosive potential.
From a July 21st low of $.4225, AVCO made a move to a high of $.8050 two weeks late on August 4th.
Boom. 90% just like that.
That was followed up soon after by a move from September 26th low of $.42 to a September 30th high of $.79.
88% in less than a week.
Most recently, AVCO blazed a path from a low of $.38 on November 1st to a high of $.595 on November 4th.
56% in a blink.
Explosive. Short term. Mover. Just look at the chart for yourself.
No. 3 AVCO Potential Catalyst - Company Receives Notice Of Allowance Related To QTY Protein Platform
Avalon GloboCare Receives Allowance for Joint U.S. Patent
Jointly with MIT, the Company also Submitted a New U.S. Patent Application for QTY Glucose Transporters
FREEHOLD, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today provided an update regarding the Company’s intellectual property portfolio featuring its QTY protein code technology.
The Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) related to its QTY fusion water-soluble receptor protein platform. The patent was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT) and covers seven claims related to the technology.
The Company also submitted a new patent application to the USPTO related to its QTY glucose transporter technology. This patent application was also jointly filed with Dr. Shuguang Zhang of MIT. QTY glucose transporters are deregulated in many tumor types and are potentially important targets for cancer therapy.
The “QTY Code,” is a breakthrough technology that can turn difficult to work with water-insoluble transmembrane receptor proteins into water-soluble proteins, enabling their potential use in many clinical applications, including drug development.
Avalon’s proprietary AVA-Trap™ technology utilizes the artificial intelligence (AI) enhanced QTY Code technology to turn receptor molecules into antibody-like decoy receptors that are able to mop up cytokines and chemokines, which are excessively produced during pathological conditions, such as CV-19 and cancer metastasis.
“We continue to strengthen our IP portfolio as we believe our novel QTY code protein design technology holds great potential for biotechnology applications and could generate significant clinical advancements in cellular immunotherapy and immune-oncology,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. “Our AI-enhanced protein design QTY Code technology co-developed with MIT’s Dr. Zhang is a novel platform that produces water-soluble proteins for a wide spectrum of biomedical applications including the design and construction of novel targets for application in cellular immunotherapy.”
“We are also pleased to submit a new patent application to the USPTO related to QTY glucose transporters, which are important cancer therapy targets. We believe using the QTY technology will accelerate our understanding of these proteins and the development of antibodies against them to treat cancer,” said Dr. Jin.
Read the full article here.
No. 4 AVCO Potential Catalyst - New Publication In Top-Ranked Journal Is Turning Heads
Avalon GloboCare Announces Publication Featuring QTY Code Technology in the Official Journal of the American Chemical Society
Findings support utility of QTY protein code as a novel platform to generate water-soluble proteins for wide spectrum of biomedical applications
Reports plans to apply for additional patents related to QTY code applications jointly with MIT
FREEHOLD, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced a new publication featuring the Company’s QTY protein code technology in Chemical Reviews, a top-ranked peer-reviewed scientific journal and the official journal of American Chemical Society (journal Impact Factor is 72). The publication, entitled “Protein Design: From the Aspect of Water Solubility and Stability,” focuses on the innovative QTY protein design code—co-developed by Avalon—as a novel platform to generate water-soluble proteins for a wide spectrum of biomedical applications. The Company initially licensed the technology from the Massachusetts Institute of Technology (MIT) and has advanced the platform through a sponsored research agreement with the university.
“We are excited to have the technology we developed together with MIT’s Dr. Zhang featured in this publication,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. “Over the past 70 years, there has been rapid advancement in the understanding of how biology works at the molecular level. Our QTY protein design code extends this knowledge, enabling an even more precise understanding and manipulation of protein structures and function. Not only does the QTY code contribute significantly to the knowledge base of an important class of proteins, but we believe it also provides new pathways for further investigation and subsequent applications that were previously unattainable. Importantly, we believe this publication is a validation of Avalon’s strategy. We previously licensed patents from MIT related to the use of QTY solubilized membrane proteins to be used as decoy receptors in therapeutics. We subsequently filed additional patent applications jointly with MIT, and plan to apply for more patents with the university related to the QTY protein design technologies.”
Read the full article here.
No. 5 AVCO Potential Catalyst - A Game-Changing New Study Featuring AI Enhanced Protein Design "QTY Code" Tech
Avalon GloboCare Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer
FREEHOLD, N.J., June 30, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced a new study applying artificial intelligence (AI) enhanced protein design “QTY Code” technology. The method is expected to accelerate development of therapeutic monoclonal antibodies to treat cancer.
Read the full article here.
AVCO Recap: These Potential Catalysts Could Fuel A Vertical Move For This Nasdaq Profile
No. 1 - Could A Squeeze Be Nearing As AVCO Approaches Its 200-Day SMA?
No. 2 - Low Float Could Allow For Daily Volatility (+ Explosive Chart History)
No. 3 - Company Receives Notice Of Allowance Related To QTY Protein Platform
No. 4 - New Publication In Top-Ranked Journal Is Turning Heads
No. 5 - A Game-Changing New Study Featuring AI Enhanced Protein Design "QTY Code" Tech
Coverage is officially reinitiated on AVCO. When time permits, do this: